Retension Pharmaceuticals Earnings Call Transcripts

Fiscal Year 2026

3rd Annual Guggenheim Healthcare Innovation Conference

RTN-001 is designed to reach central vasculature and lower blood pressure through a PDE5 mechanism outside the RAS axis. A 280-patient Phase II-B is underway, with data anticipated in H1 2027.

Read full transcript →